ECSP11010885A - Heteroarilos sustituidos - Google Patents

Heteroarilos sustituidos

Info

Publication number
ECSP11010885A
ECSP11010885A EC2011010885A ECSP11010885A ECSP11010885A EC SP11010885 A ECSP11010885 A EC SP11010885A EC 2011010885 A EC2011010885 A EC 2011010885A EC SP11010885 A ECSP11010885 A EC SP11010885A EC SP11010885 A ECSP11010885 A EC SP11010885A
Authority
EC
Ecuador
Prior art keywords
heteroarilos
substituted
glucokinase
disorders
act
Prior art date
Application number
EC2011010885A
Other languages
English (en)
Inventor
Jeffrey A Pfefferkorn
John Willian Benbow
Jihong Lou
Meihua Mike Tu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11010885(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP11010885A publication Critical patent/ECSP11010885A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona compuestos de Fórmula (1A)que actúan como activadores de glucoquinasa; composiciones farmacéuticas de los mismos; y métodos para tratar enfermedades, trastornos o afecciones mediadas por glucoquinasa. X, Y, Z, R1, R2, R3 y R4 son como se han descrito en la presente memoria.
EC2011010885A 2008-09-11 2011-03-11 Heteroarilos sustituidos ECSP11010885A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9605608P 2008-09-11 2008-09-11
US23257809P 2009-08-10 2009-08-10

Publications (1)

Publication Number Publication Date
ECSP11010885A true ECSP11010885A (es) 2011-04-29

Family

ID=41228587

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010885A ECSP11010885A (es) 2008-09-11 2011-03-11 Heteroarilos sustituidos

Country Status (29)

Country Link
US (4) US7977367B2 (es)
EP (1) EP2344458A1 (es)
JP (2) JP4907746B2 (es)
KR (1) KR101258331B1 (es)
CN (1) CN102216276A (es)
AP (1) AP2011005613A0 (es)
AR (1) AR073283A1 (es)
AU (1) AU2009290474A1 (es)
BR (1) BRPI0918128A2 (es)
CA (1) CA2735184C (es)
CL (1) CL2011000478A1 (es)
CO (1) CO6361937A2 (es)
CR (1) CR20110103A (es)
DO (1) DOP2011000076A (es)
EA (1) EA201100311A1 (es)
EC (1) ECSP11010885A (es)
GE (1) GEP20135793B (es)
IL (1) IL211411A0 (es)
MA (1) MA32627B1 (es)
MX (1) MX2011002613A (es)
NI (1) NI201100050A (es)
NZ (1) NZ591366A (es)
PA (1) PA8842101A1 (es)
PE (1) PE20110303A1 (es)
SV (1) SV2011003855A (es)
TW (1) TWI382026B (es)
UY (1) UY32098A (es)
WO (1) WO2010029461A1 (es)
ZA (1) ZA201101364B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127439A1 (en) * 2009-05-06 2010-11-11 Bellus Health (International) Limited Ammo acid derivatives for the treatment of neuropathic pain
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
KR20130130737A (ko) * 2010-11-11 2013-12-02 사노피 ３­（６­아미노­피리딘­３일）­２­아크릴산 유도체의 제조방법
WO2013113719A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds ii
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113781A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds i
US9055750B2 (en) 2012-02-03 2015-06-16 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US9072301B2 (en) 2012-02-03 2015-07-07 Basf Se Fungicidal pyrimidine compounds
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113782A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
JP2015512891A (ja) 2012-03-13 2015-04-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
EP2871180B1 (en) 2012-07-04 2018-03-21 Agro-Kanesho Co., Ltd. 2-aminonicotinic acid ester derivative and bactericide containing same as active ingredient
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
AR099677A1 (es) 2014-03-07 2016-08-10 Sumitomo Chemical Co Compuesto heterocíclico fusionado y su uso para el control de plagas
WO2018017910A1 (en) 2016-07-22 2018-01-25 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
TW201840578A (zh) * 2017-02-22 2018-11-16 以色列商亞當阿甘公司 製備甲基膦酸丁基酯的方法
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN109134535B (zh) * 2018-10-22 2021-03-19 江苏长青农化股份有限公司 一种甲基磷酸酯的制备方法
WO2022043322A1 (en) * 2020-08-25 2022-03-03 Helmholtz-Zentrum für Infektionsforschung GmbH INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB
IL308096A (en) 2021-07-08 2023-12-01 Ishihara Sangyo Kaisha Nematicidal compound

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
US5399564A (en) 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
CA2116863A1 (en) 1992-07-03 1994-01-20 Sumio Yokota Condensed heterocyclic derivatives and herbicides
EP0772610B9 (de) 1994-07-22 2001-07-25 Byk Gulden Lomberg Chemische Fabrik GmbH Dihydrobenzofurane
DE4434637A1 (de) 1994-09-28 1996-04-04 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
RU2128655C1 (ru) 1994-10-13 1999-04-10 Пфайзер Инк. Бензопирановые и бензоконденсированные соединения, промежуточные соединения, фармацевтическая композиция и способ ингибирования
NZ285154A (en) 1994-10-13 1998-11-25 Pfizer Optionally heterocyclically substituted benzopyran and benzo-fused derivatives, preparation and use as leukotriene antagonists
DE19603576A1 (de) 1996-02-01 1997-08-07 Bayer Ag Acylierte 4-Amino und 4-Hydrazinopyrimidine
CZ371998A3 (cs) 1996-05-20 1999-03-17 Darwin Discovery Limited Benzofuranové karboxamidy a jejich terapeutické použití
JP4309475B2 (ja) 1996-08-19 2009-08-05 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンゾフラン―４―カルボキサミド
WO1999040085A1 (en) 1998-02-09 1999-08-12 Darwin Discovery Limited Benzofuran-4-carboxamides and their therapeutic use
IL143929A0 (en) 1999-01-22 2002-04-21 Elan Pharm Inc Acyl derivatives which treat vla-4 related disorders
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
HUP0500543A2 (hu) 2000-11-20 2005-09-28 Bristol-Myers Squibb Company Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
ATE316965T1 (de) * 2000-12-06 2006-02-15 Hoffmann La Roche Kondensierte heteroaromatische glucokinaseaktivatoren
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
CA2433090A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CA2464214C (en) 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
ES2334990T3 (es) 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
CN100357283C (zh) 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
BR0309764A (pt) 2002-05-03 2005-02-15 Warner Lambert Co Antagonistas de bombesina
EP1511733A2 (en) 2002-06-13 2005-03-09 E.I. Du Pont De Nemours And Company Pyrazole and pyrrole carboxamide insecticides
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1433778A1 (en) 2002-12-23 2004-06-30 Jerini AG Use of nitriles as rotamase inhibitors
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
WO2004076420A1 (ja) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
CN1852906A (zh) 2003-07-15 2006-10-25 史密丝克莱恩比彻姆公司 新化合物
US7696365B2 (en) 2003-08-01 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
CN1960995B (zh) * 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
AU2005267884B2 (en) 2004-07-29 2011-04-21 Merck Sharp & Dohme Corp. Potassium channel inhibitors
WO2006028833A1 (en) 2004-09-01 2006-03-16 Rigel Pharmaceuticals, Inc. Synthesis of 2,4-pyrimidinediamine compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
MX2007007480A (es) 2004-12-21 2007-07-20 Hoffmann La Roche Derivados de cromano y su uso como ligandos del receptor 5-ht.
JP4167218B2 (ja) 2004-12-22 2008-10-15 株式会社メタル建材 薄板用タッピンねじ
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
MX2007012448A (es) 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
RU2008112184A (ru) 2005-08-31 2009-10-10 Астеллас Фарма Инк. (Jp) Производное тиазола
JP2009013065A (ja) 2005-10-14 2009-01-22 Astellas Pharma Inc 縮合へテロ環化合物
CN101360720A (zh) 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基嘧啶酮衍生物及其用途
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US20090247554A1 (en) 2006-03-30 2009-10-01 Takeda San Diego, Inc. Kinase inhibitors
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
JP2010138073A (ja) 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
EP2155720B1 (en) 2007-06-08 2013-07-17 Advinus Therapeutics Private Limited Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
TWI445707B (zh) * 2008-05-16 2014-07-21 Takeda California Inc 葡萄糖激酶活化劑
WO2010084428A1 (en) 2009-01-20 2010-07-29 Pfizer Inc. Substituted pyrazinone amides

Also Published As

Publication number Publication date
US20110230445A1 (en) 2011-09-22
PA8842101A1 (es) 2010-04-21
PE20110303A1 (es) 2011-05-21
JP4907746B2 (ja) 2012-04-04
AR073283A1 (es) 2010-10-28
NI201100050A (es) 2011-09-27
ZA201101364B (en) 2012-04-25
TWI382026B (zh) 2013-01-11
JP2012092115A (ja) 2012-05-17
DOP2011000076A (es) 2011-03-31
CN102216276A (zh) 2011-10-12
US20130165452A1 (en) 2013-06-27
MA32627B1 (fr) 2011-09-01
EA201100311A1 (ru) 2011-10-31
KR101258331B1 (ko) 2013-04-26
BRPI0918128A2 (pt) 2015-11-24
WO2010029461A1 (en) 2010-03-18
US8389552B2 (en) 2013-03-05
AP2011005613A0 (en) 2011-04-30
US20120225910A1 (en) 2012-09-06
US20100063063A1 (en) 2010-03-11
JP5225452B2 (ja) 2013-07-03
CL2011000478A1 (es) 2011-06-17
IL211411A0 (en) 2011-05-31
US7977367B2 (en) 2011-07-12
UY32098A (es) 2010-04-30
CA2735184A1 (en) 2010-03-18
CA2735184C (en) 2013-05-28
SV2011003855A (es) 2011-05-16
CR20110103A (es) 2011-03-14
NZ591366A (en) 2012-05-25
EP2344458A1 (en) 2011-07-20
TW201010998A (en) 2010-03-16
CO6361937A2 (es) 2012-01-20
MX2011002613A (es) 2011-05-23
JP2012502091A (ja) 2012-01-26
AU2009290474A1 (en) 2010-03-18
GEP20135793B (en) 2013-03-25
US8329920B2 (en) 2012-12-11
KR20110043748A (ko) 2011-04-27

Similar Documents

Publication Publication Date Title
ECSP11010885A (es) Heteroarilos sustituidos
CO6430427A2 (es) Derivados de benzofuranilo
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
MX389288B (es) Compuestos heterocíclicos útiles como inhibidores de proteína cinasa-1 dependiente de 3-fosfoinositido (pdk1).
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
BR112014030474A2 (pt) novos compostos bicíclicos de tiofenilamida
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CO6321288A2 (es) Sales de compuestos inhibidores de vih
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CR11273A (es) Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica
BR112013003121A2 (pt) moduladores de trpv3
UY32385A (es) Amidas de pirazinona sustituida
UY29631A1 (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica
SV2011003821A (es) Compuestos de fenantrenona, composiciones y metodos
UY32447A (es) Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia
CU20110054A7 (es) Derivados heteroaril amida y sus usos como glucoquinasa activadores